Sign in
4

Changes in Ownership

CYTOKINETICS INC Filed Acc 0001127602-24-019272

EVP Research & Development sold 7,300 shares at an average $53.72 ($392,143)

  • EVP Research & Development acquired 5,300 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Malik Fady Ibraham EVP Research & Development 2024-06-25 Sale 10b5-1 −2,000 $53.74 $107,480 133,004 D: show line 1 in the form
Malik Fady Ibraham EVP Research & Development 2024-06-25 Option exercise 10b5-1 +5,300 $7.96 $42,188 138,304 D: show line 2 in the form
Malik Fady Ibraham EVP Research & Development 2024-06-25 Sale 10b5-1 −5,300 $53.71 $284,663 133,004 D: show line 3 in the form
Open-market sales · 7,300 sh · avg $53.72 · $392,143

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Malik Fady Ibraham EVP Research & Development 2024-06-25 Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 −5,300 63,600 D: show line 4 in the form
Loading xslF345X05/form4.xml…